Zydus’s novel drug saroglitazar hit the primary endpoint in a Phase IIb trial for MASH but other key data are held back for a reveal at forthcoming liver Congresses. The investigative drug faces hotter competition and a broader MASH pipeline in the US post approval of Novo’s semaglutide.